NeoSphere研究的生物标志物分析:帕妥珠单抗、曲妥珠单抗和多西他赛与曲妥珠单抗加多西他赛、帕妥珠单抗加曲妥珠单抗或帕妥珠单抗加多西他赛用于her2阳性乳腺癌的新辅助治疗

IF 6.1 1区 医学 Q1 ONCOLOGY
G. Bianchini, A. Kiermaier, G. Bianchi, Y. Im, T. Pieńkowski, Mei-Ching Liu, L. Tseng, M. Dowsett, L. Zabaglo, S. Kirk, T. Szado, J. Eng-Wong, L. Amler, P. Valagussa, L. Gianni
{"title":"NeoSphere研究的生物标志物分析:帕妥珠单抗、曲妥珠单抗和多西他赛与曲妥珠单抗加多西他赛、帕妥珠单抗加曲妥珠单抗或帕妥珠单抗加多西他赛用于her2阳性乳腺癌的新辅助治疗","authors":"G. Bianchini, A. Kiermaier, G. Bianchi, Y. Im, T. Pieńkowski, Mei-Ching Liu, L. Tseng, M. Dowsett, L. Zabaglo, S. Kirk, T. Szado, J. Eng-Wong, L. Amler, P. Valagussa, L. Gianni","doi":"10.1186/s13058-017-0806-9","DOIUrl":null,"url":null,"abstract":"","PeriodicalId":9222,"journal":{"name":"Breast Cancer Research","volume":null,"pages":null},"PeriodicalIF":6.1000,"publicationDate":"2017-02-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"83","resultStr":"{\"title\":\"Biomarker analysis of the NeoSphere study: pertuzumab, trastuzumab, and docetaxel versus trastuzumab plus docetaxel, pertuzumab plus trastuzumab, or pertuzumab plus docetaxel for the neoadjuvant treatment of HER2-positive breast cancer\",\"authors\":\"G. Bianchini, A. Kiermaier, G. Bianchi, Y. Im, T. Pieńkowski, Mei-Ching Liu, L. Tseng, M. Dowsett, L. Zabaglo, S. Kirk, T. Szado, J. Eng-Wong, L. Amler, P. Valagussa, L. Gianni\",\"doi\":\"10.1186/s13058-017-0806-9\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"\",\"PeriodicalId\":9222,\"journal\":{\"name\":\"Breast Cancer Research\",\"volume\":null,\"pages\":null},\"PeriodicalIF\":6.1000,\"publicationDate\":\"2017-02-09\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"83\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Breast Cancer Research\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.1186/s13058-017-0806-9\",\"RegionNum\":1,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q1\",\"JCRName\":\"ONCOLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Breast Cancer Research","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1186/s13058-017-0806-9","RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"ONCOLOGY","Score":null,"Total":0}
引用次数: 83

摘要

本文章由计算机程序翻译,如有差异,请以英文原文为准。
Biomarker analysis of the NeoSphere study: pertuzumab, trastuzumab, and docetaxel versus trastuzumab plus docetaxel, pertuzumab plus trastuzumab, or pertuzumab plus docetaxel for the neoadjuvant treatment of HER2-positive breast cancer
求助全文
通过发布文献求助,成功后即可免费获取论文全文。 去求助
来源期刊
Breast Cancer Research
Breast Cancer Research 医学-肿瘤学
自引率
0.00%
发文量
76
期刊介绍: Breast Cancer Research is an international, peer-reviewed online journal, publishing original research, reviews, editorials and reports. Open access research articles of exceptional interest are published in all areas of biology and medicine relevant to breast cancer, including normal mammary gland biology, with special emphasis on the genetic, biochemical, and cellular basis of breast cancer. In addition to basic research, the journal publishes preclinical, translational and clinical studies with a biological basis, including Phase I and Phase II trials.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信